89bio's pegozafermin, an FGF21 analog, is currently being evaluated in three Phase III trials. Two of these trials are focused on different MASH populations, while the third targets SHTG patients.
Hosted on MSN1mon
89bio seeks $250 million in public stock offeringThe securities in this offering are exclusively from 89bio. The firm plans to allocate the net proceeds to further clinical trials of its leading drug candidate, pegozafermin, as well as ...
(NASDAQ:ETNB – Get Free Report)‘s stock had its “sell (d-)” rating reiterated by stock analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports. Several other brokerages ...
H.C. Wainwright lowered the firm’s price target on 89bio (ETNB) to $21 from $29 and keeps a Buy rating on the shares. The company announced ...
89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of pegozafermin, manufacturing related costs and other general corporate ...
89bio reported a net loss of $118.4 million ... The company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis ...
CEO of 89bio.“We remain confident in pegozafermin's potential as a potent anti-fibrotic agent with broad cardio-metabolic benefits. With a strengthened leadership team, commercial-scale ...
89bio announced a public offering of 21.67 ... The company is focused on advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction ...
30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or ... extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated ...
ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic ...
SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq ... and convenient dosing, pegozafermin has the potential to significantly impact the lives of patients suffering from advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback